Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.04 USD | +2.87% |
|
+9.37% | +9.97% |
05-03 | Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target | MT |
03-07 | Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.97% | 588M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- PHAT Stock
- News Phathom Pharmaceuticals, Inc.
- Phathom Pharmaceuticals : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40